Capricor Therapeutics (CAPR) CFO Bergmann Buys $1.3K of Stock
Anthony Bergmann, CFO of Capricor Therapeutics, bought 400 shares on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Anthony Bergmann, CHIEF FINANCIAL OFFICER at Capricor Therapeutics, Inc. ($CAPR), bought 400 shares at an average price of $3.18, worth about $1,272, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CAPR is down 21.8% after 1 week, down 33.2% after 1 month and down 77.3% to date (from the $29.51 close on Jun 24, 2026).
CAPR
Capricor Therapeutics, Inc.
Key Points
- On June 24, 2026, CFO Anthony Bergmann bought 400 shares of Capricor Therapeutics for a total of $1,272, at a price of $3.18 each.
- Capricor Therapeutics' stock is currently priced at $29.51, well above its 52-week low of $2.96, reflecting its volatility in the biotechnology sector.
- The company has a market cap of approximately $517.4 million and is actively developing treatments for Duchenne muscular dystrophy.
Get $CAPR trade alerts by text
We text you when insiders, Congress or big funds trade $CAPR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Capricor Therapeutics, Inc. alert may contain errors. Disclosures
CFO Makes a Purchase
On June 24, 2026, Anthony Bergmann, the Chief Financial Officer of Capricor Therapeutics, Inc. (NasdaqGS: CAPR), bought 400 shares at a price of $3.18 each. This purchase totaled about $1,272.
Insider Buying and Selling at Capricor Therapeutics, Inc.
This transaction fits into a pattern for Bergmann, who sold 24,100 shares on June 25, 2026, valued at approximately $76,638. Just days before, on June 22, he also sold shares valued at $15,000.
How Capricor Therapeutics, Inc. Stock Has Traded
Capricor Therapeutics' stock is currently trading at $29.51, significantly higher than its 52-week low of $2.96. The stock has shown considerable volatility, reaching a high of $40.37 in the past year.
Recent Earnings
Capricor Therapeutics is set to release its next earnings report on November 10, 2026. The company is focused on developing innovative therapies for Duchenne muscular dystrophy and other unmet medical needs.
What Capricor Therapeutics, Inc. Does
Capricor Therapeutics, based in San Diego, is a biotechnology firm developing cell and exosome-based therapies. Its lead product is in phase 3 trials for treating Duchenne muscular dystrophy, aiming to address significant health challenges.
What's Ahead for Capricor Therapeutics, Inc.
Investors will be watching for Capricor's next earnings report and any further insider transactions. The recent trades by CFO Bergmann may signal confidence in the company's future prospects, although they follow a pattern of selling in the past week.
Related Filing Alerts
Source: Anthony Bergmann's Form 4 filing on $CAPR (Jun 24, 2026). Find the original filing: CAPR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts